anti ace2  (R&D Systems)

Journal: Bioactive Materials

Article Title: Spatiotemporally engineered microneedle for microenvironment remodeling propels mucosal regeneration after tracheal mucosal injury

doi: 10.1016/j.bioactmat.2026.01.026

Figure Lengend Snippet: Gel-AgNA/MgGA MN promote mucosal regeneration. (a) HE and Safranin O staining of rabbit tracheal samples harvested at Day 10 post-operation after treated with Gel, Gel-AgNA, Gel-MgGA, and Gel-AgNA/MgGA MN. (b) IF staining of CK14 (marker of basal cells, red) and AC-Tub (marker of cilia cell, green). (c) IF staining of ZO-1 (marker of tight junctions, orange). (d, e) Quantitative analysis of regenerated epithelial coverage and thickness (n = 9). (f) Masson and Sirius Red staining for collagen evaluation after various treatments (n = 5). Quantitative analysis of collagen volume fraction (g) and fiber orientation (h) . The pentagram indicates luminal side of trachea.

Article Snippet: Immunofluorescence staining of CK14 (Abcam, ab181595), AC-Tub (Proteintech, 66200-1-Ig), ZO-1 (Proteintech, 21773-1-AP), and Immunohistochemical (IHC) staining for CD31 (Servicebio, S1002) were conducted to reveal the conditions of mucosal regeneration, according to previous literature [ ].

Techniques: Staining, Marker

Journal: Signal Transduction and Targeted Therapy

Article Title: Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

doi: 10.1038/s41392-026-02650-3

Figure Lengend Snippet: Analysis of anti-tumor macrophage activation in the TME post-iMac treatment. Tumors were harvested and single-cell suspensions were prepared for flow cytometry analysis as detailed in the methods section (refer to Fig. ). a Gating strategy for distinguishing M1 and M2 macrophages using flow cytometry based on surface marker immunostaining. b Assessment of CD86 + (M1) and CD206 + (M2) expression in tumor associated macrophages (TAMs) in SK-MEL-28-derived xenografts (±Dox). The bar plot presents FACS quantification of M1 and M2 populations ( n = 5/group). c Assessment of arginase expression in TAMs. d ACE expression in TAMs. e – g Measurement of proinflammatory and anti-tumor markers IFN-γ, IL-12, and iNOS (left: representative histogram; right: mean fluorescence intensity) in TAMs in melanoma xenografts ( n = 5/group). Statistical analysis was performed using a two-sided unpaired Student’s t -test for comparisons in ( b , d , g ), and one-way ANOVA with Bonferroni’s correction for multiple comparisons in ( c , e , f ). Data are presented as means ± SEM. * p < 0.05 and **** p < 0.0001

Article Snippet: For ACE immunostaining, cells were first treated with a mouse anti-ACE primary antibody (R&D Systems, MAB9291, 1:100), followed by an Alexa Fluor 647 anti-mouse secondary antibody (Invitrogen, A-21235, 1:500).

Techniques: Activation Assay, Single Cell, Flow Cytometry, Marker, Immunostaining, Expressing, Derivative Assay, Fluorescence

Journal: Signal Transduction and Targeted Therapy

Article Title: Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

doi: 10.1038/s41392-026-02650-3

Figure Lengend Snippet: Determination of anti-tumor activity of iMac with induced ACE expression, in vitro. a Proliferation of melanoma (SK-MEL-28), Triple Negative Breast Cancer (TNBC: HCC1806), and FP chemotherapy resistant HNSCC (FaDu/FP-R) cell lines cultured alone or indirectly co-cultured with iMac ( ± Dox) using 3.0 µm pore polyester membrane inserts for 5 days. Total and dead cell counts were determined via trypan blue exclusion on days 1, 3, and 5. b , c Quantification of iNOS and interleukin-12 (IL-12) production in Cnt-iMac and ACE-iMac treated with LPS (500 ng/ml, 12 h), ± Dox. d ROS production in ACE-iMac following LPS stimulation (1 µg/ml, 30 min) ±Dox, assessed by DCFDA (2’,7’-dichlorodihydrofluorescein diacetate) staining. Representative histograms (left) and mean fluorescence intensity (MFI) quantification (right) are shown. Nitric Oxide (NO) production in ACE-iMac stimulated with LPS (75 ng/ml) for 24 h ( e ), and/or conditioned with SK-MEL-28 supernatant for 24 h ( f ) ± Dox. g Perforin and IFN-γ levels in human peripheral blood NK and Tc cells, respectively, after co-culture with Cnt-iMac or ACE-iMac pretreated with LPS (24 h), followed by melanoma conditioning (24 h). To induce ACE expression, myeloid progenitors were differentiated in the presence of Dox and maintained at 1 µg/ml throughout all in vitro assays. Experiments were performed in triplicates across three independent replicates. Statistical analyses included one-way ANOVA ( a ), two-way ANOVA with Bonferroni correction ( b , c , g ), and two-sided unpaired Student’s t -test ( d – f ). Data are presented as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

Article Snippet: The polyvinylidene difluoride (PVDF) membranes were incubated with specific primary antibodies against ACE (R&D Systems, MAB9291, 1:1,000), GAPDH (Sigma-Aldrich, SAB5600208, 1:2,000), β-actin (Sigma-Aldrich, A3854; 1:1000), phosphorylated NF-kB p65 (Novus, NB100-82086, 1:500), phosphorylated STAT1 (R&D Systems, AF2894, 1 μg/ml), phosphorylated STAT3 (Novus, NBP2-24463, 0.5 μg/ml), or phosphorylated STAT6 (Millipore, 06-937, 1:1000).

Techniques: Activity Assay, Expressing, In Vitro, Cell Culture, Membrane, Staining, Fluorescence, Co-Culture Assay

Journal: Signal Transduction and Targeted Therapy

Article Title: Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

doi: 10.1038/s41392-026-02650-3

Figure Lengend Snippet: Analysis of anti-tumor macrophage activation in the TME post-iMac treatment. Tumors were harvested and single-cell suspensions were prepared for flow cytometry analysis as detailed in the methods section (refer to Fig. ). a Gating strategy for distinguishing M1 and M2 macrophages using flow cytometry based on surface marker immunostaining. b Assessment of CD86 + (M1) and CD206 + (M2) expression in tumor associated macrophages (TAMs) in SK-MEL-28-derived xenografts (±Dox). The bar plot presents FACS quantification of M1 and M2 populations ( n = 5/group). c Assessment of arginase expression in TAMs. d ACE expression in TAMs. e – g Measurement of proinflammatory and anti-tumor markers IFN-γ, IL-12, and iNOS (left: representative histogram; right: mean fluorescence intensity) in TAMs in melanoma xenografts ( n = 5/group). Statistical analysis was performed using a two-sided unpaired Student’s t -test for comparisons in ( b , d , g ), and one-way ANOVA with Bonferroni’s correction for multiple comparisons in ( c , e , f ). Data are presented as means ± SEM. * p < 0.05 and **** p < 0.0001

Article Snippet: The polyvinylidene difluoride (PVDF) membranes were incubated with specific primary antibodies against ACE (R&D Systems, MAB9291, 1:1,000), GAPDH (Sigma-Aldrich, SAB5600208, 1:2,000), β-actin (Sigma-Aldrich, A3854; 1:1000), phosphorylated NF-kB p65 (Novus, NB100-82086, 1:500), phosphorylated STAT1 (R&D Systems, AF2894, 1 μg/ml), phosphorylated STAT3 (Novus, NBP2-24463, 0.5 μg/ml), or phosphorylated STAT6 (Millipore, 06-937, 1:1000).

Techniques: Activation Assay, Single Cell, Flow Cytometry, Marker, Immunostaining, Expressing, Derivative Assay, Fluorescence

Journal: Signal Transduction and Targeted Therapy

Article Title: Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

doi: 10.1038/s41392-026-02650-3

Figure Lengend Snippet: The effect of ACE-iMac treatment on human immune cells in a humanized mouse tumor model. a Growth of SK-MEL-28 tumors in humanized BLT-NSG mice; comparing tumor volumes between PBS, iMac and ACE-iMac treated groups. b Representative images of tumors are shown (see Supplementary Fig. for additional images). c Final tumor volumes on Day 28 post-implantation. d Tumor weight on Day 28 post-implantation. Flow cytometry analysis of anti-tumor activation of human CD8 T cells in the TME, measured by intracellular IFN-γ ( e ) and perforin ( f ) in tumor-infiltrating CD3 + CD8 + T cells at sacrifice on Day 28 post-implantation. g Flow cytometry analysis of anti-tumor activation of NK cells, measured by intracellular IFN-γ in tumor-infiltrating CD45 + CD56 + NK cells in the TME on Day 28. The flow cytometry gating strategy for identifying human immune cells is provided in Supplementary Fig. . One-way ANOVA with Bonferroni’s correction for multiple comparisons was used to analyze group comparisons. Data are presented as means ± SEM ( n = 9–10). * p < 0.05, ** p < 0.01, and **** p < 0.0001

Article Snippet: The polyvinylidene difluoride (PVDF) membranes were incubated with specific primary antibodies against ACE (R&D Systems, MAB9291, 1:1,000), GAPDH (Sigma-Aldrich, SAB5600208, 1:2,000), β-actin (Sigma-Aldrich, A3854; 1:1000), phosphorylated NF-kB p65 (Novus, NB100-82086, 1:500), phosphorylated STAT1 (R&D Systems, AF2894, 1 μg/ml), phosphorylated STAT3 (Novus, NBP2-24463, 0.5 μg/ml), or phosphorylated STAT6 (Millipore, 06-937, 1:1000).

Techniques: Flow Cytometry, Activation Assay